Ibrutinib is the first approved therapy for symptomatic patients with Waldenstr€ om macroglobulinemia (WM). The reasons for discontinuing ibrutinib and subsequent outcomes have not been previously evaluated in WM patients. We therefore conducted a retrospective review of 189 WM patients seen at our institution who received treatment with ibrutinib, of whom 51 (27%) have discontinued therapy. Reasons for discontinuation include: disease progression (n 5 27; 14%), toxicity (n 5 15; 8%), nonresponse (n 5 5; 3%), and other unrelated reasons (n 5 4; 2%). The cumulative incidence of ibrutinib discontinuation at 12, 24, 36, and 48 months from treatment initiation was 22%, 26%, 35%, and 43%, respectively. A baseline platelet count 100 K/mL and presence of tumor CXCR4 mutations were independently associated with 4-fold increased odds of ibrutinib discontinuation. An IgM rebound (25% increase in serum IgM) was observed in 37 patients (73%) following ibrutinib discontinuation and occurred within 4 weeks for nearly half of patients. The response rate to salvage therapy was 71%; responses were higher in patients without an IgM rebound and when salvage therapy was initiated within 2 weeks of stopping ibrutinib. Patients who discontinued ibrutinib due to disease progression versus nonprogression events had significantly shorter overall survival (21 versus 32 months; P 5 .046). Response to salvage therapy was associated with an 82% reduction in the risk of death following ibrutinib discontinuation. WM patients who discontinue ibrutinib require close monitoring, and continuation of ibrutinib until the next therapy should be considered to maintain disease control.
Ibrutinib therapy was associated with both a high overall response rate (91%) and major response rate (73%), and an estimated 24-month progression-free and overall survival of 69% and 95%,
respectively. An important finding was the role of MYD88 and CXCR4 mutation status as determinants of ibrutinib response.
Patients with wild-type (WT) MYD88 had no major responses, while mutated MYD88 patients with a CXCR4 mutation had fewer major responses versus those with WT CXCR4 (62% versus 92%). 10 Delayed major response attainment (>6 months) was also observed for CXCR4 mutated patients. Treatment was generally well tolerated; neutropenia (22%) and thrombocytopenia (14%) were the only related grade 2 adverse events occurring in >10% of patients. On the basis of these results, ibrutinib became the first approved therapy for WM by the United States (US) Food and Drug Administration and the European Medicines Agency. Similar findings have since been reported in a multicenter study with 31 WM patients who were refractory to rituximab, and in a phase II study evaluating ibrutinib as primary therapy for WM patients. 11, 12 Am J Hematol. 2018;93:511-517.
wileyonlinelibrary.com/journal/ajh Despite the durable activity and tolerability of ibrutinib in WM, treatment discontinuation will be required for some patients due to unacceptable toxicity or disease progression. Discontinuation of ibrutinib has been associated with an adverse prognosis in patients with chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). [13] [14] [15] [16] However, outcomes following ibrutinib discontinuation in patients with WM have not been previously evaluated. We therefore reviewed our experience with WM patients treated with ibrutinib who subsequently stopped therapy to determine their clinicopathological characteristics, prognostic factors, and outcomes.
| M E TH ODS

| Patient selection and variable identification
We performed a retrospective review of patients seen at our institution between May 2012 and April 2017 who met clinicopathological criteria for WM and received ibrutinib therapy. 1 Patient charts were manually reviewed to identify patients who discontinued ibrutinib for any reason. Pertinent clinical and pathological data were collected from the time of ibrutinib initiation to last follow-up or death. Response assessment to ibrutinib therapy was defined according to international guidelines. 17 The presence of MYD88 and CXCR4 mutations were determined by allele-specific polymerase chain reaction and Sanger sequencing methods, as previously described.
4,18
| Statistical considerations
Patient characteristics are presented using descriptive characteristics.
Continuous variables were categorized to facilitate analysis, and comparisons were made using the Chi-square and Fischer exact test. Univariate and multivariate logistic regression models were fit to evaluate the association between clinicopathological variables, and the risk of ibrutinib discontinuation and an IgM rebound; the outcome measure was odds ratio (OR) with 95% confidence interval (CI). An IgM rebound was defined as a 25% increase in serum IgM level, with an absolute increase of at least 500 mg/dL, following discontinuation of ibrutinib.
The time to events was estimated using the Kaplan-Meier method for incomplete observations, and comparisons between groups were made using the log-rank test. The Cox-proportional hazard regression method was used to fit univariate and multivariate models for overall survival; the outcome measure was hazard ratio (HR) with 95% CI. P-values <.10 were included in the multivariate analysis. Table 1 . WM patients who discontinued ibrutinib were more likely to have a baseline platelet count 100 K/mL (22% versus 7%; P 5 .006) and harbor a CXCR4 mutation (60% versus 27%; P < .001) compared to patients who did not discontinue ibrutinib.
| Risk of ibrutinib discontinuation
The cumulative incidence of ibrutinib discontinuation at 12, 24, 36, and 48 months from treatment initiation was 22%, 26%, 35%, and 43%, respectively ( Figure 1A ). The median time to ibrutinib discontinuation was 7 months (95% CI 6-9). By univariate analysis, a baseline serum IgM level >4000 mg/dL, serum b 2 -microglobulin level >3.0 mg/l, and treatment for extramedullary disease were associated with lower odds of ibrutinib discontinuation, whereas a baseline platelet count 100 K/ mL and CXCR4 mutation were associated with higher odds of ibrutinib discontinuation. Age, sex, hemoglobin level, bone marrow involvement, International Prognostic Scoring System for WM (IPSSWM) score, treatment indication, prior treatment status, or MYD88 mutation status were not associated with higher or lower odds of ibrutinib discontinuation. In the multivariate analysis, a baseline platelet count 100 K/mL (OR 3.85, 95% 1.20-12.3; P 5 .02) and CXCR4 mutation (OR 3.89, 95% CI 1.74-8.69; P 5 .001) were independently associated with higher odds of ibrutinib discontinuation. A baseline serum IgM level >4000 mg/dL (OR 0.38, 95% CI 0.17-0.86; P 5 .02) also remained associated with lower odds of ibrutinib discontinuation. The univariate and multivariate models for ibrutinib discontinuation are shown in Table 2 .
Ibrutinib was discontinued in 27 patients (14%) due to progressive disease (PD). The cumulative incidence of ibrutinib discontinuation at 12, 24, 36, and 48 months was 13%, 13%, 15%, and 15%, respectively 
| Salvage therapy
Thirty-eight patients (75%) received salvage therapy following ibrutinib discontinuation. The median time to salvage therapy was 5 weeks (95% CI 3.6-8.1). The cumulative incidence of salvage therapy at 4, 8, and 12 weeks following ibrutinib discontinuation was 37%, 62%, and 72%, respectively. Patients discontinuing ibrutinib due to PD versus non-PD events had a shorter time to the initiation of salvage therapy Patients without an IgM rebound were more likely to respond to salvage therapy versus those with an IgM rebound (100% versus 62%; P 5 .04). Moreover, response rates were higher among PD patients who began salvage therapy 2 versus >2 weeks from ibrutinib discontinuation (100% versus 57%; P 5 .02), whereas no difference was observed for patients with non-PD ibrutinib discontinuation (P 5 .58).
Thirteen patients (24%) have not received salvage therapy, of whom 9 discontinued ibrutinib due to a non-PD event. Reasons for not receiving salvage therapy include: treatment not required (n 5 6; 46%), patient choice (n 5 4; 31%), death due to progressive disease (n 5 2; 15%), and acute myeloid leukemia (n 5 1; 8%). 
| Survival analysis
| D I SCUSSION
Ibrutinib is the first approved therapy for symptomatic patients with WM. Understanding the factors responsible for ibrutinib discontinuation and subsequent outcomes may help direct management strategies to optimize patient care, and was the focus of this retrospective study.
Our most salient results can be summarized as follows: (i) 22% of WM patients discontinue ibrutinib within one year of initiation; (ii) discontinuation due to toxicity or nonresponse is more common early in therapy and becomes progressively infrequent; (iii) disease progression on active therapy is uncommon with an estimated 4-year rate of 15%; (iv) a baseline platelet count 100 K/mL and CXCR4 mutations are independently associated with 4-fold increased odds of discontinuation; (v) nearly half of WM patients experience an IgM rebound within 4 weeks of stopping ibrutinib; and (vi) response to salvage therapy is associated with an 82% reduction in the risk of death following ibrutinib discontinuation.
Our data show WM patients with CXCR4 mutations are more likely to discontinue ibrutinib therapy. This expands upon prior studies demonstrating CXCR4 mutations confer both in vitro and clinical resistance to ibrutinib. [7] [8] [9] 11 Acquired BTK C481S mutations are also strongly associated with CXCR4 mutations in the development of ibrutinib resistance. 19 Importantly, 80% of patients deemed to be ibrutinib nonresponders in our cohort harbored a CXCR4 mutation, and all discontinued ibrutinib within 6 months of treatment initiation. It is possible the decision to stop ibrutinib in these patients may have been premature given the limited treatment duration. In the pivotal phase II trial, objective responses to ibrutinib were less likely at 6 months in WM patients with mutated versus WT CXCR4 (62% versus 91%); however, higher response rates were seen in CXCR4 mutated patients with prolonged ibrutinib exposure. 9 Alternative therapies should therefore be considered in CXCR4 mutated patients requiring immediate disease control. 20 Only three MYD88 WT patients in our study cohort were exposed to ibrutinib. These were patients enrolled in our initial clinical trial. Treatment with ibrutinib is generally not recommended in MYD88
WT patients given the limited activity in this population. 9, 10, 20 These findings emphasize how MYD88 and CXCR4 mutation status can be useful in the therapeutic management of WM patients.
An important observation was the occurrence of an IgM rebound in most patients following ibrutinib discontinuation. Abrupt increases in serum IgM levels can potentiate IgM-related morbidity in WM patients, 17 Moreover, cessation of STAT5A inhibition likely contributes to the IgM rebound described herein, as well as the transient increases in serum IgM level observed when ibrutinib is temporarily withheld due to toxicity or procedures. 9, 27 It is noteworthy that these serum IgM increases may persist for more than six months following ibrutinib reinstitution, and do not necessarily indicate treatment failure. 28 Akin to CLL and MCL, outcomes were less favorable for WM patients with disease progression versus those discontinuing ibrutinib for other reasons. [13] [14] [15] [16] We identified response to salvage therapy as an 
